Arcellx Inc

Gilead’s $7.8 billion acquisition of Arcellx boosts its cell‑based oncology portfolio, integrating the Anito‑cel platform for faster, personalized immunotherapies.

Arcellx Inc. (ALEX) gains analyst confidence amid stock volatility and competitive pressure from Kelonia, offering investors a potential entry point in adaptive‑immune oncology.

Arcellx, Inc. is a development-stage pharmaceutical company pioneering adaptive immune cell therapies to combat cancer, despite experiencing market fluctuations and a significant decrease in stock value.